SCHEMBL4582684

SCHEMBL4582684

O=C(O)c1ccc(N2C(=O)c3cccc4cccc(c34)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 7/20 1.00
CA12 O43570 5/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
RXFP1 Q9HBX9 2/20 1.00
CA1 P00915 5/20 0.73
CA2 P00918 3/20 0.73
SCN2A Q99250 1/20 0.73
KDM4E B2RXH2 5/20 0.68
POLB P06746 2/20 0.68
RECQL P46063 2/20 0.68
CASP6 P55212 2/20 0.68
TDP1 Q9NUW8 2/20 0.68
APEX1 P27695 1/20 0.68
CTDSP1 Q9GZU7 1/20 0.68
ALDH1A1 P00352 4/20 0.64
PPARA Q07869 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.59
HPGD P15428 2/20 0.59
PDE6D O43924 1/20 0.54
CA4 P22748 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20735193 0.86 ALDH1A1 (0.82) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL3841868 0.86 L3MBTL1 (0.75) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL28166422 0.86 CA9 (0.75) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL16589414 0.86 CA9 (0.75) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL31663432 0.84 CA9 (1.00) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL481667 0.84 CA9 (1.00) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL10061703 0.84 CA9 (0.73) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL1514286 0.84 L3MBTL1 (0.73) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL16601986 0.83 CA9 (0.77) CA9CA12L3MBTL1RXFP1CA1
SCHEMBL299841 0.83 ALDH1A1 (0.71) CA9CA12L3MBTL1RXFP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
EP-3049387-B1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & CO (US) 2020-11-11 EP disclosed
EP-3049387-B1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & CO (US) 2020-11-11 EP disclosed
EP-3049387-A1 THERMOPLASTIC POLYMER COMPOSITION Milliken & Company (US) 2016-08-03 EP disclosed
EP-3049468-A1 THERMOPLASTIC POLYMER COMPOSITION Milliken & Company (US) 2016-08-03 EP disclosed
EP-3049388-A1 THERMOPLASTIC POLYMER COMPOSITION Milliken & Company (US) 2016-08-03 EP disclosed
EP-3049469-A1 THERMOPLASTIC POLYMER COMPOSITION Milliken & Company (US) 2016-08-03 EP disclosed
US-9200144-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9200144-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9200142-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
WO-2015042563-A1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & COMPANY (US) 2015-03-26 WO disclosed
US-8501046-B2 Use of rylene derivatives as photosensitizers in solar cells BASF SE (DE) 2013-08-06 US disclosed
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS MAX-PLANCK-GESEL. ZUR FOERDERUNG DER WISSEN. E.V. (DE) 2012-11-08 US disclosed
US-8231809-B2 Solid p-semiconductors may also be used in the inventive dye-sensitized solar cells without increasing the cell resistance, since the rylene derivatives absorb strongly and therefore require only thin n-semiconductor layers BASF AKTIENGESELLSCHAFT (DE) 2012-07-31 US disclosed
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells BASF SE (DE) 2008-10-30 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283432-A1 USE OF RYLENE DERIVATIVES AS PHOTOSENSITIZERS IN SOLAR CELLS NR2E3, NR2E1, NR1D2 CA9 3076/4885CA12 2135/4885L3MBTL1 2444/4885
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 CA9 3754/4885CA12 1700/4885L3MBTL1 4441/4885
US-20080269482-A1 Use of Rylene Derivatives as Photosensitizers in Solar Cells NR2E3, NR2E1, NR1D2 CA9 3139/4885CA12 2183/4885L3MBTL1 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.